The in-silico drug discovery industry analysis projects the market to grow at a significant CAGR of 12.92% during the forecast period, 2019-2029. The in-silico drug discovery market generated $2,094.5 million in revenue in 2018, in terms of value.
The global in-silico drug discovery market growth has been primarily attributed to the major drivers in this market such as an emphasis on the reduction in medical errors and readmission rates, growth in the biomarker identification market and advancements in In-silico drug discovery techniques, and computational technological advancements in the field of computational biology.
However, there are significant challenges that are restraining the market growth. These challenges include the high cost of methods and expensive procedures and their applications in medical treatments.
North America is the leading contributor to the in-silico drug discovery market and contributed approximately 41.65% to the global market value in 2018. This region is anticipated to grow at a significant CAGR during the forecast period 2019-2029 and continue dominating the global market in 2029. However, the Asia-Pacific region is expected to grow at the highest CAGR of 13.29% during the forecast period. In addition, the region of Europe also contributed a significant share of 28.40% to the global market in 2018.
Scope of the Market Intelligence
The in-silico drug discovery research provides a holistic view of the market in terms of various factors influencing it, including regulatory reforms, and technological advancements.
The scope of this report is centered upon conducting a detailed study of the products and manufacturers allied with the service market. In addition, the study also includes exhaustive information on the unmet needs, perception of the new products, competitive landscape, market share of leading manufacturers, the growth potential of each underlying sub-segment, and company, as well as other vital information with respect to the global in-silico drug discovery market.
Key Companies in the Market
The key manufacturers who have been contributing significantly to the global in-silico drug discovery market include Albany Molecular Research Inc., Certara USA, Inc., Charles River, Chemical Computing Group ULC, Collaborative Drug Discovery Inc., Dassault System (Biovia), Evotec A.G., GVK Biosciences Private Limited, ICAGEN, INC., Novo Informatics Pvt. Ltd., Numerate Inc., PerkinElmer Inc, Schrdinger, LLC, Selvita, Simulation Plus, and WuXi AppTec, among others.
Key Questions Answered in the Report
What are the major market drivers, challenges, and opportunities in the global in-silico drug discovery market?
What are the underlying structures resulting in the emerging trends within the global in-silico drug discovery market?
How is each segment of the global in-silico drug discovery market expected to grow during the forecast period and what is the estimated revenue to be generated by each of the segments by the end of 2029?
What is the expected compound growth rate to be witnessed by the leading players in the market during the forecast period 2019-2029?
What are the key applications in the global in-silico drug discovery market? What are the major segments of these applications?
Who are the key manufacturers of the global in-silico drug discovery market, and what are their contributions?
Key Topics Covered
1 Product Definition 1.1 Inclusion and Exclusion
2 Research Scope 2.1 Scope of the Study 2.2 Key Questions Answered in the Report
3 Research Methodology 3.1 Global In-Silico Drug Discovery Market: Research Methodology 3.2 Primary Data Sources 3.3 Secondary Data Sources 3.4 Market Estimation Model
4 Industry Analysis 4.1 Regulatory Framework 4.1.1 Regulatory Framework in North America 4.1.2 Regulatory Framework in Europe 4.1.3 Regulatory Framework in Asia-Pacific
5 Competitive Landscape 5.1 Mergers and Acquisitions 5.2 Product Launches and Product Updates 5.3 Synergistic Activities 5.4 Business Expansion Activities and Others 5.5 Market Share Analysis
6 Market Dynamics 6.1 Overview 6.2 Impact Analysis 6.3 Market Drivers 6.3.1 Emphasis on Reduction in Medical Errors and Readmission Rates 6.3.2 Growth in the Biomarker Identification Market and Advancements in In-Silico Drug Discovery Techniques 6.3.3 Technological Advancements in the Field of Computational Biology 6.4 Market Restraints 6.4.1 Lack of High Complexity Testing Centers 6.4.2 Expensive Procedures and Their Applications in Medical Treatments 6.4.3 High Capital Requirement Hampering the Expansion of Global Reach 6.5 Market Opportunities 6.5.1 Massive Scope for Adoption of In-Silico Drug Discovery in Developing Nations 6.5.2 Integration of Blockchain Technology in Interoperability 6.5.3 Collaborations With Precision Medicine Providers
7 In-Silico Drug Discovery: Overview 7.1 Introduction 7.2 Market Availability for In-Silico Drug Discovery 7.3 In-Silico Drug Discovery Market Technology Trends
9 Global In-Silico Drug Discovery Market (by Product) 9.1 Software 9.2 Software as-a-Service (Cloud) 9.3 Consultancy as-a-Service
10 Global In-Silico Drug Discovery Market (by Software Type) 10.1 Molecular Modeling and de Novo Drug Design Software 10.2 Pharmacophore Modeling Software
11 Global In-Silico Drug Discovery Market (by End-user) 11.1 Contract Research Organizations 11.2 Pharmaceutical Industry 11.3 Academic and Research Institutes 11.4 Other End-users (Hospitals and Other Care Facilities)
12 Global In-Silico Drug Discovery Market, by Region 12.1 Overview 12.2 North America 12.2.1 U.S. 12.2.2 Canada 12.3 Europe 12.3.1 Germany 12.3.2 France 12.3.3 U.K. 12.3.4 Italy 12.3.5 Spain 12.3.6 Russia 12.3.7 Rest-of-Europe 12.4 Asia-Pacific 12.4.1 China 12.4.2 Japan 12.4.3 Australia 12.4.4 India 12.4.5 South Korea 12.4.6 Rest-of-APAC 12.5 Latin America 12.5.1 Brazil 12.5.2 Mexico 12.6 Rest-of-the-World
13 Company Profiles 13.1 Overview 13.2 Albany Molecular Research Inc. 13.2.1 Company Overview 13.2.2 Role of Albany Molecular Research in the Global In-Silico Drug Discovery Market 13.2.3 SWOT Analysis 13.3 Certara USA Inc. 13.4 Charles River 13.5 Chemical Computing Group ULC 13.6 Collaborative Drug Discovery Inc. 13.7 Dassault System (Biovia) 13.8 Evotec AG 13.9 GVK Biosciences Private Limited 13.10 ICAGEN Inc. 13.11 Novo Informatics Pvt. Ltd. 13.12 Numerate Inc. 13.13 PerkinElmer Inc. 13.14 Schrdinger LLC 13.15 Selvita 13.16 Simulation Plus 13.17 WuXi AppTec 13.18 e-therapeutics plc (Snapshot)